Insmed Reports Disappointing Trial Results


Insmed Inc. (Nasdaq: INSM) reported disappointing results from a Phase II clinical trial of its myotonic muscular dystrophy treatment IPLEX sending the stock price plummeting $1.29 to $1.04.

About this Entry

This page contains a single entry by published on June 25, 2009 10:36 AM.

China Architectural Wins $500 Million Contract was the previous entry in this blog.

Sales Rise For Lennar is the next entry in this blog.

Find recent content on the main index or look in the archives to find all content.

Powered by Movable Type 5.12